Gemini Space Station Inc vs Moderna, Inc. — how do they compare? Gemini Space Station Inc trades at $4.02 (market cap $512.05M), while Moderna, Inc. trades at $60.38 (market cap $24.18B). The key difference: Moderna, Inc. is far larger — about 47.2× Gemini Space Station Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Gemini Space Station Inc nearer its low. Which is the better fit depends on your goals.
| GEMI | MRNA | |
|---|---|---|
Market Cap | $512.05M | $24.18B |
Sector | Technology | Health |
52-Week High | $32.52 | $81.80 |
52-Week Low | $3.90 | $22.36 |
Enterprise Value | $502.04M | $20.33B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.
Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.
Trailing returns across standard periods
Latest headlines on both assets
Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.
Read more on GEMI →Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →